MedTrace Logo

Salivary Alpha Amylase as a Biomarker of Transdermal Vagus Nerve Stimulation

NCT03854539 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2020-06-18

No results posted yet for this study

Summary

The proposed project tests the hypothesis that salivary alpha amylase concentration is a reliable biomarker of the effect of transdermal vagus nerve stimulation (tVNS) in humans.

Conditions

  • No Condition Salivary Alpha Amylase

Interventions

OTHER

Transdermal Vagus Nerve Stimulation

intermittent transdermal stimulation of the aurical vagus

Sponsors & Collaborators

  • Arkansas Tech University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-03-31
Primary Completion
2020-06-08
Completion
2020-06-08

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03854539 on ClinicalTrials.gov